Current aspects of stable ischemic heart disease. ISСHEMIA study: breakthrough or constant optimism in approaches to treatment. Myocardial ischemia in non-obstructive coronary arteries (INOCA)

Approaches to stable coronary artery disease (CАD) treatment have been subject to debate for a long time. One of the first and fundamental studies in stable coronary artery disease patients treatment is the COURAGE study, which showed the advantage of rational drug therapy in comparison with percutaneous intervention in such patients. However, CAD high prevalence with medical and social significance cause the need for future development of relationship between conservative and invasive approaches in the problem of this disease treatment. It was particularly the focus of recently completed multicentre ISCHEMIA trail. The aim of review is to analyze the available data on the management of stable coronary artery disease patients based on the ISCHEMIA study data. Results. In the largest multicenter randomized clinical trial ISCHEMIA, the primary outcome (cardiovascular death, myocardial infarction, cardiac arrest with effective resuscitation, hospitalization due to heart failure) rate was 13.3% in the routine invasive strategy group and 15.5% in the conservative strategy group (p = 0.34). The main secondary outcome rate also does not differ between groups significantly. Quality of life in the non-invasive group was higher only in those patients who had angina at baseline. Study subanalysis demonstrated that left coronary artery borderline stenosis accompanied by a poor prognosis, and an invasive strategy improves angina symptoms. Also, low density lipoprotein cholesterol target values achievement predictors were determined. In addition, women, participated in ISCHEMIA study had more frequent angina episodes, regardless less extensive coronary artery damage, and less severe ischemia manifestations than men. Among stable CAD accompanied moderate to severe ischemia and severe chronic kidney disease patients, no evidence initial invasive strategy, compared initial conservative strategy, in relation of death or non-fatal myocardial infarction risk reduction was found. Conclusion: ISCHEMIA trial data demonstrated necessity more carefully stable coronary artery disease patients selection for invasive treatment, taking into account angina pectoris severity and modern antianginal therapy possibilities.

1. Андреенко Е. Ю., Явелов И. С., Лукьянов М. М. и др. Ишемическая болезнь сердца у лиц молодого возраста: особенности этиологии, клинических проявлений и прогноза. Кардиология, 2018; 58 (11): 24–34. doi: 10.18087/cardio.2018.11.10195

2. Рекомендации ЕSC по диагностике и лечению хронического коронарного синдрома. Рос. кардиол. журн., 2020; 25 (2): 119–182.

3. Бойцов С. А., Погосова Н. В., Бубнова М. Г. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Рос. кардиол. журн., 2018; 23 (6): 118 с.

4. Аронов Д. М., Лупанов В. П. Исследование COURAGE: обескураживают или воодушевляют его результаты? Кардиоваскуляр. терапия и профилактика, 2007; 7 (7): 95–104.

5. Maron D.J., Mancini G. B., Hartigan P. M. et al. Healthy behavior, risk factor control, and survival in the COURAGE trial. J. Am. Coll. Cardiol., 2018; 72 (19): 2297–2305. doi: 10.1016/j.jacc.2018.08.2163

6. ISCHEMIA Trial Research Group, Maron D.J., Hochman J. S. et al. International study of comparative health effectiveness with medical and invasive approaches (ISCHEMIA) trial: Rationale and design. Am. Heart J., 2018; 201: 124–135. doi: 10.1016/j.ahj.2018.04.011

7. Берштейн Л. Л., Збышевская Е. В., Катамадзе Н. О., Кузьмина-¬Крутецкая А.М и др. ISCHEMIA — крупнейшее в истории рандомизированное исследование по стабильной ишемической болезни сердца. Исходные характеристики включенных пациентов на примере российского центра. Кардиология, 2017; 57 (10): 12–19. doi: 10.18087/cardio.2017.10.10038

8. Maron D.J., Hochman J. S., Reynolds H. R. et al. Initial invasive or conservative strategy for stable coronary disease. N. Engl. J. Med., 2020; 382: 1395–407.

9. Spertus J.A., Jones P. G., Maron D.J. et al. Health-¬status outcomes with invasive or conservative care in coronary disease. N. Engl. J. Med., 2020; 82: 1408–1419.

10. Bangalore S. ISCHEMIA: Intermediate left main disease confers poor prognosis; invasive strategy improves angina symptoms. https://www.healio.com/news/cardiac-vascular-intervention/20200514/ischemia-intermediateleft-main-disease-confers-poor-prognosis-invasive-strategy-improves-angina-sym

11. Newman J. D., Alexander K. P., Gu X. et al. Baseline predictors of low-density lipoprotein cholesterol and systolic blood pressure goal attainment after 1 year in the ISCHEMIA trial. Circ. Cardiovasc. Qual. Outcomes, 2019; 12 (11): e006002. doi: 10.1161/CIRCOUTCOMES.119.006002

12. Reynolds H. R., Shaw L.J., Min J. K. et al. Association of sex with severity of coronary artery disease, ischemia, and symptom burden in patients with moderate or severe ischemia: Secondary analysis of the ISCHEMIA randomized clinical trial. JAMA Cardiol., 2020; 5 (7): 773–786. doi: 10.1001/jamacardio.2020.0822

13. Bangalore S., Maron D.J., O’Brien S.M. et al. Management of coronary disease in patients with advanced kidney disease. N. Engl. J. Med., 2020; 382: 1608–1618 doi: 10.1056/NEJMoa1915925

14. Bangalore S., Maron D.J., Fleg J. L., O’Brien S. M. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. N. Engl. J. Med., 2020; 382 (17): 1608–1618. doi: 10.1056/NEJMoa1915925.

15. Kunadian V., Chieffo A., Camici P. G., Berry C. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European society of cardiology working group on coronary pathophysiology and microcirculation endorsed by coronary vasomotor disorders international study group. EuroIntervention, 2021, 16 (13): 1049–1069. doi: 10.4244/EIJY20M07_01

16. Claudio Ch.P., Quesada O., Pepine C.J., Merz C. N.B. Why names matter for women: MINOCA/INOCA (myocardial infarction/ ischemia and no obstructive coronary artery disease. Clin. Cardiol., 2018; 41 (2): 185–193. doi: 10.1002/clc.22894